We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+10.05%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$630M
AUM Growth
+$66.5M
Cap. Flow
+$74.6M
Cap. Flow %
11.85%
Top 10 Hldgs %
30.71%
Holding
120
New
23
Increased
22
Reduced
38
Closed
13

Top Buys

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$79.9M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$14.1M
3
MRK icon
Merck
MRK
+$12.3M
4
AGN
Allergan plc
AGN
+$6.72M
5
BMY icon
Bristol-Myers Squibb
BMY
+$6.42M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$20M
2
PFE icon
Pfizer
PFE
+$13.2M
3
MDT icon
Medtronic
MDT
+$11M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$8.02M
5
CPHD
Cepheid Inc
CPHD
+$8M

Sector Composition

Rank Sector Weight
1 Healthcare 86.01%
2 Financials 0.83%
3 Technology 0.09%
4 Energy 0.06%
5 Industrials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LH icon
51
Labcorp
LH
$25.9B
$4.12M 0.66%
34,920
-17,460
-33% -$2.06M
RDUS
52
DELISTED
Radius Health, Inc.
RDUS
$4.06M 0.64%
75,000
-25,000
-25% -$1.27M
TMO icon
53
Thermo Fisher Scientific
TMO
$220B
$3.98M 0.63%
+25,000
New +$3.85M
CEMP
54
DELISTED
Cempra, Inc.
CEMP
$3.9M 0.62%
161,000
-10,000
-6% -$215K
ARRY
55
DELISTED
Array Biopharma Inc
ARRY
$3.71M 0.59%
550,000
+180,000
+49% +$696K
UHS icon
56
Universal Health Services
UHS
$10.5B
$3.7M 0.59%
+30,000
New +$3.8M
DVA icon
57
DaVita
DVA
$11.7B
$3.63M 0.58%
+55,000
New +$3.87M
NXTM
58
DELISTED
NxStage Medical Inc.
NXTM
$3.63M 0.58%
145,300
– –
COO icon
59
Cooper Companies
COO
$14.5B
$3.59M 0.57%
80,000
-20,000
-20% -$911K
CHRS icon
60
Coherus Oncology
CHRS
$196M
$3.52M 0.56%
131,357
– –
RVNC
61
DELISTED
Revance Therapeutics, Inc.
RVNC
$3.4M 0.54%
210,000
-10,000
-5% -$145K
PRGO icon
62
Perrigo
PRGO
$1.78B
$3.23M 0.51%
35,000
+15,000
+75% +$1.38M
DVAX
63
DELISTED
Dynavax Technologies
DVAX
$3.15M 0.5%
300,000
+150,000
+100% +$2.16M
CMRX
64
DELISTED
Chimerix, Inc.
CMRX
$3.05M 0.48%
550,000
– –
HALO icon
65
Halozyme
HALO
$12.2B
$3.02M 0.48%
250,000
– –
PTLA
66
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$2.74M 0.44%
120,805
+15,805
+15% +$371K
NDRM
67
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$2.67M 0.42%
144,546
– –
KERX
68
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$2.66M 0.42%
500,111
+50,000
+11% +$270K
PODD icon
69
Insulet
PODD
$9.79B
$2.33M 0.37%
57,000
-25,000
-30% -$988K
RAD
70
DELISTED
Rite Aid Corporation
RAD
$2.31M 0.37%
+15,000
New +$2.24M
TSRO
71
DELISTED
TESARO, Inc.
TSRO
$2.16M 0.34%
+21,500
New +$2.01M
ACHN
72
DELISTED
Achillion Pharmaceuticals
ACHN
$2.15M 0.34%
266,000
– –
KYNB
73
Kyntra Bio
KYNB
$29.4M
$2.15M 0.34%
4,160
-400
-9% -$188K
ADMS
74
DELISTED
Adamas Pharmaceuticals
ADMS
$2.13M 0.34%
130,000
– –
ITCI
75
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$2.06M 0.33%
135,000
+20,000
+17% +$809K
1 2
3
4 5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q3 2016 Portfolio in Review

As of Q3 2016, Rhenman & Partners Asset Management held 120 positions worth $630M, up 12% from $563M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rhenman & Partners Asset Management deployed $74.6M of net new capital in Q3 2016, opening 23 new positions and adding to 22 existing holdings. Its largest new stake was Shire pic: 409,858 shares worth $26.6M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 94% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $8.02M trimmed.

  • Rhenman & Partners Asset Management's largest Q3 2016 buy was Shire pic: 409,858 shares worth $26.6M.
  • Rhenman & Partners Asset Management added most to Allergan plc in Q3 2016, an estimated $6.72M increase.
  • Rhenman & Partners Asset Management's biggest Q3 2016 reduction was Regeneron Pharmaceuticals, cutting an estimated $8.02M.
  • Rhenman & Partners Asset Management fully exited Gilead Sciences in Q3 2016, selling an estimated $20M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 31% of its $630M portfolio in Q3 2016.
  • Rhenman & Partners Asset Management opened 23 new positions and closed 13 in Q3 2016.
  • Rhenman & Partners Asset Management's portfolio value rose 12% quarter-over-quarter to $630M.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2016, filed 8 Nov 2016.